logo
The US fertility rate reached a new low in 2024, CDC data shows

The US fertility rate reached a new low in 2024, CDC data shows

NEW YORK (AP) — The fertility rate in the U.S. dropped to an all-time low in 2024 with less than 1.6 kids per woman, new federal data released Thursday shows.
The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all.
The new statistic is on par with fertility rates in western European countries, according to
World Bank data
.
Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an
executive order
meant to expand access to and reduce costs of in vitro fertilization and backing the idea of
'baby bonuses'
that might encourage more couples to have kids.
But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy.
'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said.
The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with
updated birth data
for 2024.
In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics.
Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina.
People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment.
'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said.
Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care.
'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said.
Increase in births in new data
The CDC's new report, which is based on a more complete review of birth certificates than
provisional data
released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year.
That brought the yearly national total to just over 3.6 million babies born.
But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s.
What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate.
That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's Hand Makeup Reappears on Overseas Trip to Scotland
Trump's Hand Makeup Reappears on Overseas Trip to Scotland

Yahoo

timean hour ago

  • Yahoo

Trump's Hand Makeup Reappears on Overseas Trip to Scotland

President Trump has packed his faithful supply of hand make-up for his trip to Scotland. Photographs of Trump meeting European Commission President Ursula von der Leyen on Sunday reveal the persistent bruising on his right hand continues to be covered with heavy concealer. The president was announcing a trade deal between the U.S. and Europe when cameras panned to his hand. The White House referred the Daily Beast to a July 17 medical report that diagnosed the president with chronic venous insufficiency, saying it was a benign and common condition, particularly in individuals over the age of 70. The White House also referred to Press Secretary Karoline Leavitt's remarks that, 'The president remains in excellent health.' The bruising on his hand was particularly visible as the president spoke to the media on the South Lawn on the White House on Friday before he departed for Scotland on Marine One. The mysterious ailment on Trump's hand made news in February when the large bruise was noticed during French President Emmanuel Macron's visit to the White House. It has become a talking point ever since. It was also spotted last Thursday during Trump's visit to the Federal Reserve headquarters on Thursday. The bruise was later explained as being a byproduct of hand-shaking by the White House. Leavitt told the Daily Beast earlier this month that Trump is 'a man of the people and he meets more Americans and shakes their hands on a daily basis than any other president in history.' Last week, Leavitt produced a letter from the White House physician to address the issue of Trump's swelling and bruising, confirming Trump had been seen for a check-up. The 'comprehensive examination' of the 79-year-old concluded he had Chronic Venous Insufficiency (CVI), which occurs when the veins cannot manage blood flow well, making it hard for the blood to return to the heart. Physician Sean Barbabella said in his report, 'Recent photos of the president have shown minor bruising on the back of his hand. This is consistent with minor soft tissue irritation from frequent handshaking and the use of aspirin, which is taken as part of a standard cardiovascular prevention regimen.' He added, 'This is a well-known and benign side effect of aspirin therapy.'

Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia
Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia

Business Wire

time3 hours ago

  • Business Wire

Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal® in Saudi Arabia

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth® - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, obtains marketing authorization (MA) and reimbursement status for Sibnayal® (a fixed combination of potassium citrate and potassium bicarbonate) in the Kingdom of Saudi Arabia (KSA). Marketing authorization for Sibnayal® (ADV7103) in distal Renal Tubular Acidosis (dRTA) in KSA has been granted, based on the European registration dossier. Furthermore, Saudi authorities have agreed a reimbursement rate in line with the best European pricing. This achievment results of a close collaboration between Advicenne and its local partner, Taïba Healthcare, a leading distributor of pharmaceutical products in the Gulf region. Advicenne will act as the marketing authorization holder, while Taïba Healthcare will manage local marketing activities. The incidence of dRTA is higher in Gulf countries than in Europe or the United States, and prevalence in KSA could be estimated around 600 to 800 patients. Sibnayal® is already prescribed through early access programs in several Gulf countries outside Saudi Arabia. This milestone paves the way for registrations in GCC countries where the application is filed. Didier Laurens, CEO of Advicenne, declared: 'I am particularly proud of this important achievement and wish to congratulate both Advicenne and Taïba Healthcare teams, whose efforts were instrumental in informing and convincing the Saudi health authorities. The reimbursement obtained, comparable to the highest levels recorded in Europe, further attests to the significant therapeutic value of Sibnayal® in a region with one of the highest prevalence rates of dRTA worldwide.' About Advicenne Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: Disclaimer This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2024 Universal Registration Document filed with the French financial market authority on April 29, 2025 (a copy of which is available on and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.

COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.
COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.

Yahoo

time4 hours ago

  • Yahoo

COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.

COVID-19 numbers are rising in Massachusetts, and in states across the country. "COVID-19 laboratory percent positivity is increasing nationally," according to the Centers for Disease Control and Prevention (CDC) website. "Emergency department visits for COVID-19 are increasing among young children 0-4 years old," though the CDC noted that emergency room visits are "low" overall. The latest COVID-19 strain is known as "Nimbus." Here's what to know. Are COVID-19 numbers increasing in Massachusetts? The CDC website has evaluated the issue in each state and determined cases in Massachusetts are likely rising. In Massachusetts, there is an 85.8% chance that COVID-19 numbers are increasing, according to the CDC. The Massachusetts Department of Public Health (DPH) reported that as of June 28, there were 377 confirmed cases of COVID and 77 unconfirmed cases. No COVID-19 deaths were reported at the time. The data stops in June because the Massachusetts DPH "ended data collection for the 2024-2025 viral respiratory season on June 28, 2025, and routine updates to their dashboard for the 2025-2026 season will resume later this summer." What is the current COVID-19 strain 'Nimbus?' As of early June, the new strain known as NB.1.8.1, or "Nimbus," made up 37% of COVID-19 cases nationwide. Variant NB.1.8.1 was first detected in China in January 2025 but accounted for about 0% of cases in the United States until May. The World Health Organization added at the time that currently approved COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease." Virologists describe Nimbus as a 'slightly upgraded' version of its predecessor. While there is no evidence it causes more severe disease, it appears to be highly transmissible. What are the symptoms of Nimbus? Reported symptoms of NB.1.8.1 are similar to other COVID-19 strains, but one distinctive complaint is a severe sore throat, sometimes described as 'razor-blade throat fatigue.' Other symptoms may include: Mild cough Fever Muscle aches Nasal congestion Are vaccines still effective? Health experts say that updated COVID-19 vaccines remain the best protection against severe illness. Vaccination rates vary widely by state, and health officials continue to urge eligible individuals to stay current with their shots. How can people get tested? People can either take an at-home test or they can see their respective doctors. (This story was updated because an earlier version included an inaccuracy.) This article originally appeared on COVID cases on rise in MA, CDC says. What to know about latest strain Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store